Invega (Paliperidone) for Depression

Overview
Invega is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and adolescents ages 12 to 17. It may be prescribed as a first-line treatment for individuals newly diagnosed with schizophrenia or for those who require ongoing maintenance therapy. Invega is also known by its drug name, paliperidone.

Invega is an atypical antipsychotic. Scientists believe it works by adjusting levels of certain brain chemicals, including dopamine and serotonin, to help reduce symptoms of schizophrenia such as hallucinations, delusions, and disorganized thinking.

How do I take it?
Prescribing information states that Invega is taken as an extended-release tablet once daily in the morning, with or without food. Dosing varies depending on a person’s age and/or body weight. Dosing may be adjusted over time, depending on how a person responds. The tablet should be swallowed whole and not chewed, divided, or crushed. Invega should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Invega in adults include extrapyramidal symptoms (movement disorders such as tremors or stiffness), tachycardia (fast heart rate), and akathisia (restlessness). In adolescents, additional common side effects include somnolence (drowsiness), tremor, dystonia (muscle contractions), cogwheel rigidity (muscle stiffness), anxiety, and weight gain.

Rare but serious side effects may include increased risk of death in older individuals with dementia-related psychosis, cerebrovascular events (such as stroke), neuroleptic malignant syndrome (a life-threatening reaction with high fever and muscle rigidity), QT prolongation (abnormal heart rhythm), tardive dyskinesia (involuntary movements), and seizures.

Other serious risks include metabolic changes such as hyperglycemia (high blood sugar), dyslipidemia (abnormal cholesterol levels), and significant weight gain. Invega may also cause high levels of prolactin, which can disrupt hormone levels, and can result in gastrointestinal narrowing, low blood pressure upon standing (orthostatic hypotension), low white blood cell counts, and cognitive or motor impairment.

For more information about this treatment, visit:

Label: Invega- Paliperidone Tablet, Extended Release — DailyMed